Dana-Farber Cancer Institute
@danafarber.bsky.social
A leading center for expert, compassionate cancer care and advanced research.
Appts: 877-442-3324 | http://dana-farber.org
Appts: 877-442-3324 | http://dana-farber.org
The list is out! More than 145 Dana-Farber affiliated faculty are recognized as 2026 Top Doctors by @bostonmagazine.bsky.social. Congratulations to all!
View the list here: bit.ly/49YcUaW
View the list here: bit.ly/49YcUaW
January 27, 2026 at 2:54 PM
The list is out! More than 145 Dana-Farber affiliated faculty are recognized as 2026 Top Doctors by @bostonmagazine.bsky.social. Congratulations to all!
View the list here: bit.ly/49YcUaW
View the list here: bit.ly/49YcUaW
We hope everyone is staying safe and warm this weekend. We will work to accommodate patients who may be delayed or need to reschedule. ❄️
January 25, 2026 at 9:30 PM
We hope everyone is staying safe and warm this weekend. We will work to accommodate patients who may be delayed or need to reschedule. ❄️
Please join us in congratulating Philip J. Kranzusch, PhD, on receiving the 2026 NAS Award in Molecular Biology. Kranzusch’s seminal work has reshaped our understanding of human innate immunity, revealing its evolutionary links to bacterial antiviral defense. Learn more: bit.ly/4roj0sj
January 25, 2026 at 2:00 PM
Please join us in congratulating Philip J. Kranzusch, PhD, on receiving the 2026 NAS Award in Molecular Biology. Kranzusch’s seminal work has reshaped our understanding of human innate immunity, revealing its evolutionary links to bacterial antiviral defense. Learn more: bit.ly/4roj0sj
Researchers in @vanallenlab.bsky.social developed an experimental AI-based oncologist’s assistant to explore how AI could support precision oncology. Early testing showed promising accuracy. The assistant is intended for research purposes, with additional study needed before clinical use.
Dana-Farber Researchers Create Experimental AI-based Oncologist’s Assistant
Published: January 15, 2026Updated: January 20, 2026Key Takeaways: Powered by large-language models that have been given a crash course in precision oncology, the AI-based oncologist’s assistant shows the potential for AI to help oncologists keep up with the fast pace of approvals of precision cancer medicines. More research is needed before such tools can be ... Read more
bit.ly
January 22, 2026 at 10:05 PM
Researchers in @vanallenlab.bsky.social developed an experimental AI-based oncologist’s assistant to explore how AI could support precision oncology. Early testing showed promising accuracy. The assistant is intended for research purposes, with additional study needed before clinical use.
Physicians, join our in-person CME "Topics in Gastrointestinal Oncology" on 2/7 for case-based guidance on managing GI cancers through expert-led discussions, interactive sessions, & practical problem-solving to enhance clinical competence. Register here: bit.ly/49Ad1ZS
Topics in Gastrointestinal Oncology | Harvard Medical School Professional, Corporate, and Continuing Education
Deliver up-to-date, case-based guidance on managing gastrointestinal cancers through expert-led discussions, interactive sessions, and practical problem-solving designed to enhance clinical competence.
bit.ly
January 16, 2026 at 4:45 PM
Physicians, join our in-person CME "Topics in Gastrointestinal Oncology" on 2/7 for case-based guidance on managing GI cancers through expert-led discussions, interactive sessions, & practical problem-solving to enhance clinical competence. Register here: bit.ly/49Ad1ZS
Lachelle Weeks, MD, PhD, treats patients with acute myeloid leukemia, one of the hardest blood cancers to treat. She believes survival rates can be improved not just with new treatments, but also by finding ways to prevent the disease before it starts.
Learn more: bit.ly/4sDXMb1
Learn more: bit.ly/4sDXMb1
January 14, 2026 at 5:05 PM
Lachelle Weeks, MD, PhD, treats patients with acute myeloid leukemia, one of the hardest blood cancers to treat. She believes survival rates can be improved not just with new treatments, but also by finding ways to prevent the disease before it starts.
Learn more: bit.ly/4sDXMb1
Learn more: bit.ly/4sDXMb1
Our researchers are using novel spatial tools to learn how immune cells affect cancer. “I don’t think we appreciated how much the spatial dynamics of the immune system matter,” says @judithagudo.bsky.social.
Learn more about what researchers are learning from this technology: bit.ly/49uOtSg
Learn more about what researchers are learning from this technology: bit.ly/49uOtSg
Seeing Is Believing | Dana-Farber Cancer Institute
Technicolor images of tumor samples are changing cancer research.
bit.ly
January 13, 2026 at 1:30 PM
Our researchers are using novel spatial tools to learn how immune cells affect cancer. “I don’t think we appreciated how much the spatial dynamics of the immune system matter,” says @judithagudo.bsky.social.
Learn more about what researchers are learning from this technology: bit.ly/49uOtSg
Learn more about what researchers are learning from this technology: bit.ly/49uOtSg
Congratulations to @goldietaylor.bsky.social, Senior Vice President, Chief Communications and Marketing Officer, on being named a finalist in the 2026 @prweekus.bsky.social Awards for Outstanding CCO/In-House Professional. View the shortlist here: bit.ly/4jFD8Ds
PRWeek US Awards 2026 shortlist revealed
PRWeek US Awards 2026 shortlist revealed. From PR Week
bit.ly
January 12, 2026 at 8:00 PM
Congratulations to @goldietaylor.bsky.social, Senior Vice President, Chief Communications and Marketing Officer, on being named a finalist in the 2026 @prweekus.bsky.social Awards for Outstanding CCO/In-House Professional. View the shortlist here: bit.ly/4jFD8Ds
Reposted by Dana-Farber Cancer Institute
New research in @science.com from @danafarber.bsky.social @ckadoch.bsky.social and Siddhant Jain, PhD, answers a longstanding question regarding recruitment of chromatin regulatory machinery and provides a new framework for development of precision medicines in #cancer.
Read more: bit.ly/452dsec
Read more: bit.ly/452dsec
January 8, 2026 at 4:40 PM
New research in @science.com from @danafarber.bsky.social @ckadoch.bsky.social and Siddhant Jain, PhD, answers a longstanding question regarding recruitment of chromatin regulatory machinery and provides a new framework for development of precision medicines in #cancer.
Read more: bit.ly/452dsec
Read more: bit.ly/452dsec
Why does cancer come back after years of remission? @nature.com shares how researchers are uncovering what causes dormant tumor cells to reawaken. @judithagudo.bsky.social offered insights into why tumor cells may enter dormancy as a protective mechanism. Read more: bit.ly/4btv5Y6
Why cancer can come back years later — and how to stop it
Researchers are targeting dormant tumour cells that might explain why some cancers reappear long after successful treatment.
bit.ly
January 8, 2026 at 4:30 PM
Why does cancer come back after years of remission? @nature.com shares how researchers are uncovering what causes dormant tumor cells to reawaken. @judithagudo.bsky.social offered insights into why tumor cells may enter dormancy as a protective mechanism. Read more: bit.ly/4btv5Y6
A novel AI-based noninvasive tool developed by investigators at Dana-Farber Cancer Institute and Mass General Brigham can predict the likelihood that cancer will spread, informing treatment decisions for patients with oropharyngeal cancer. Learn more: bit.ly/4joABNR
Novel AI Tool Offers Prognosis for Patients with Head and Neck Cancer | Dana-Farber Cancer Institute
A team led by investigators at Dana-Farber Cancer Institute and Mass General Brigham has developed and validated an artificial intelligence (AI)–based noninvasive tool that can predict the likelihood that a patient’s oropharyngeal cancer—a type of head and neck cancer that develops in the throat—will spread, thereby signaling which patients should receive aggressive treatment. The research is published in Journal of Clinical Oncology.
bit.ly
January 7, 2026 at 5:10 PM
A novel AI-based noninvasive tool developed by investigators at Dana-Farber Cancer Institute and Mass General Brigham can predict the likelihood that cancer will spread, informing treatment decisions for patients with oropharyngeal cancer. Learn more: bit.ly/4joABNR
Goldie Taylor, Senior Vice President, Chief Communications and Marketing Officer, has been named to Ragan’s Top Women in Communications, Class of 2026, recognized in the Healthcare Communicators category. Please join us in congratulating her on this recognition.
View the full list: bit.ly/4b2jyyL
View the full list: bit.ly/4b2jyyL
January 1, 2026 at 5:05 PM
Goldie Taylor, Senior Vice President, Chief Communications and Marketing Officer, has been named to Ragan’s Top Women in Communications, Class of 2026, recognized in the Healthcare Communicators category. Please join us in congratulating her on this recognition.
View the full list: bit.ly/4b2jyyL
View the full list: bit.ly/4b2jyyL
Reposted by Dana-Farber Cancer Institute
Becker’s Hospital Review reports that a noninvasive AI tool developed by @danafarber.bsky.social’s Benjamin Kann, MD, improved clinical risk stratification when integrated into existing prognostic frameworks for patients with oropharyngeal carcinoma.
Read more at bit.ly/3KSFamV
Read more at bit.ly/3KSFamV
Mass General Brigham, Dana-Farber develop AI cancer prognosis tool
Mass General Brigham Dana developed an AI tool predicting cancer spread in oropharyngeal carcinoma, improving risk stratification and outcomes.
bit.ly
December 30, 2025 at 4:30 PM
Becker’s Hospital Review reports that a noninvasive AI tool developed by @danafarber.bsky.social’s Benjamin Kann, MD, improved clinical risk stratification when integrated into existing prognostic frameworks for patients with oropharyngeal carcinoma.
Read more at bit.ly/3KSFamV
Read more at bit.ly/3KSFamV
Reposted by Dana-Farber Cancer Institute
Benjamin Ebert, MD, PhD, President and CEO of @danafarber.bsky.social, shared his perspectives with Boston Business Journal on the institute’s planned investments in AI research and rare disease drug development while keeping plans for its new hospital on track in the new year. bit.ly/3MRd5gp
December 30, 2025 at 6:30 PM
Benjamin Ebert, MD, PhD, President and CEO of @danafarber.bsky.social, shared his perspectives with Boston Business Journal on the institute’s planned investments in AI research and rare disease drug development while keeping plans for its new hospital on track in the new year. bit.ly/3MRd5gp
How much has cancer care changed in the first quarter of this century? Quite a lot, thanks to cancer research here and around the world. Get the details here: bit.ly/4pJ9Ju9
December 31, 2025 at 1:31 PM
How much has cancer care changed in the first quarter of this century? Quite a lot, thanks to cancer research here and around the world. Get the details here: bit.ly/4pJ9Ju9
Every year, physician researchers at Dana-Farber reveal new treatments, protocols, and outcomes that advance cancer research. Here are three of the most exciting — several nearing FDA approval. Read more: bit.ly/48uatxg
Three Recent Dana-Farber Research Studies to Know About
Published: November 5, 2025Written by: Maddi LangweilEvery year, physician researchers at Dana-Farber Cancer Institute reveal new treatments, protocols, and outcomes that advance cancer research. At one of this year’s biggest cancer research conferences, the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, Dana-Farber researchers presented 22 studies in breast, lung, and bladder cancer. Here are three of the most exciting advancements — several nearing U.S. Food and Drug Administration (FDA) approval — shared by our experts nearly 4,000 miles across the world. An ... Read more
bit.ly
December 30, 2025 at 1:30 PM
Every year, physician researchers at Dana-Farber reveal new treatments, protocols, and outcomes that advance cancer research. Here are three of the most exciting — several nearing FDA approval. Read more: bit.ly/48uatxg
Reposted by Dana-Farber Cancer Institute
“It feels really fulfilling and affirming, and it truly is an honor,” @danafarber.bsky.social’s Alexandria Monteiro tells @boston25news.com while donating her stem cells at the Kraft Family Blood Donor Center during the holidays to a pediatric patient needing a transplant.
➡️ bit.ly/49fDX0X
➡️ bit.ly/49fDX0X
Dana Farber employees donate life-saving stem cells to patient
Boston 25 Weather Brian Walshe Murder Trial(Opens in new window) The Local Life(Opens in new window) Share your pics(Opens in new window)
bit.ly
December 29, 2025 at 9:45 PM
“It feels really fulfilling and affirming, and it truly is an honor,” @danafarber.bsky.social’s Alexandria Monteiro tells @boston25news.com while donating her stem cells at the Kraft Family Blood Donor Center during the holidays to a pediatric patient needing a transplant.
➡️ bit.ly/49fDX0X
➡️ bit.ly/49fDX0X
“Now, for the first time ever, we’ve created a molecularly based stratification biomarker,” says pediatric oncologist Brian Crompton, MD.
The STAG2 biomarker may open the door to finding more effective treatments for Ewing sarcoma. Learn more: bit.ly/44Q2zvO
The STAG2 biomarker may open the door to finding more effective treatments for Ewing sarcoma. Learn more: bit.ly/44Q2zvO
Dana-Farber Research Opens the Door to Finding More Effective Treatments for Ewing Sarcoma
Published: November 20, 2025Written by: Beth DoughertyKey Takeaways: Molecular biomarkers have been used for more than two decades to guide cancer treatment and have transformed outcomes in many forms of cancer. For rare cancers like Ewing sarcoma, discovering clinically viable biomarkers has been a challenge — until recent research by Dana-Farber scientists. In 2014, Dana-Farber pediatric ... Read more
bit.ly
December 29, 2025 at 9:25 PM
“Now, for the first time ever, we’ve created a molecularly based stratification biomarker,” says pediatric oncologist Brian Crompton, MD.
The STAG2 biomarker may open the door to finding more effective treatments for Ewing sarcoma. Learn more: bit.ly/44Q2zvO
The STAG2 biomarker may open the door to finding more effective treatments for Ewing sarcoma. Learn more: bit.ly/44Q2zvO
We’re proud to be included in Becker’s Great Hospitals in America list, which recognizes organizations that stand out for exceptional clinical performance, unwavering focus on patient safety, and dedication to innovation, research and education. View the full list here: bit.ly/49nr2Lv
December 27, 2025 at 1:30 PM
We’re proud to be included in Becker’s Great Hospitals in America list, which recognizes organizations that stand out for exceptional clinical performance, unwavering focus on patient safety, and dedication to innovation, research and education. View the full list here: bit.ly/49nr2Lv
The COMET study led by Ann Partridge, MD, MPH, and colleagues was recognized by @jama.com as part of their "Research of the Year” roundup. Results of COMET results suggest that active monitoring could be a reasonable approach to management of low-risk DCIS. Learn more: bit.ly/492IwLS
December 24, 2025 at 1:35 PM
The COMET study led by Ann Partridge, MD, MPH, and colleagues was recognized by @jama.com as part of their "Research of the Year” roundup. Results of COMET results suggest that active monitoring could be a reasonable approach to management of low-risk DCIS. Learn more: bit.ly/492IwLS
The FDA has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. The approval is based on results from the phase III DESTINY-Breast09 study, led by Sara Tolaney, MD, Chief of Breast Oncology.
Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer | Dana-Farber Cancer Institute
The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer.
bit.ly
December 23, 2025 at 2:39 PM
The FDA has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. The approval is based on results from the phase III DESTINY-Breast09 study, led by Sara Tolaney, MD, Chief of Breast Oncology.
We’re thrilled that both our adult and pediatric stem cell/bone marrow transplant programs earned the highest possible +1 score in the 2025 CIBMTR Survival Report — exceeding expected 1-year survival nationwide. Thank you to our dedicated team and partners for advancing patient care every day.
Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants | Dana-Farber Cancer Institute
Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports. The +1 scores reflect that both programs outperformed the expected one-year survival rate for allogeneic (donor) stem cell transplants in the United States.
bit.ly
December 22, 2025 at 9:39 PM
We’re thrilled that both our adult and pediatric stem cell/bone marrow transplant programs earned the highest possible +1 score in the 2025 CIBMTR Survival Report — exceeding expected 1-year survival nationwide. Thank you to our dedicated team and partners for advancing patient care every day.
Reposted by Dana-Farber Cancer Institute
ICYMI: Breast cancer research breakthroughs discussed at #ESMO25 by @danafarber.bsky.social's Breast Oncology Center. Learn how these discoveries will impact clinical care going forward: 🎥 bit.ly/4j4fa4x
Breast Cancer Breakthroughs: ESMO25 Highlights
Share your videos with friends, family, and the world
bit.ly
December 22, 2025 at 8:45 PM
ICYMI: Breast cancer research breakthroughs discussed at #ESMO25 by @danafarber.bsky.social's Breast Oncology Center. Learn how these discoveries will impact clinical care going forward: 🎥 bit.ly/4j4fa4x
Meet Evan Chen, MD, a medical oncologist who treats patients with acute leukemias and myeloid malignancies. Learn more about his clinic research, which focuses on the development of cellular therapies for leukemias and translational studies of leukemia epigenetics: bit.ly/48ZI6rp
December 16, 2025 at 1:00 PM
Meet Evan Chen, MD, a medical oncologist who treats patients with acute leukemias and myeloid malignancies. Learn more about his clinic research, which focuses on the development of cellular therapies for leukemias and translational studies of leukemia epigenetics: bit.ly/48ZI6rp
Reposted by Dana-Farber Cancer Institute
"This gift keeps reinforcing to me the beauty in the world,” @danafarber.bsky.social oncology nurse navigator Idalina Colburn tells @wbztv.bsky.social’s Anna Meiler after Good News Movement surprised her with a trip from Expedia so her family may continue making happy memories.
➡️ bit.ly/4oUGbIX
➡️ bit.ly/4oUGbIX
Dana-Farber nurse battling cancer surprised with free vacation for family
Idalina Colburn does not let her cancer diagnosis hold her back from treating patients at Dana-Farber Cancer Institute. Her story got the attention of a group that wanted to make a difference. WBZ-TV’s Anna Meiler reports.
bit.ly
December 14, 2025 at 4:30 PM
"This gift keeps reinforcing to me the beauty in the world,” @danafarber.bsky.social oncology nurse navigator Idalina Colburn tells @wbztv.bsky.social’s Anna Meiler after Good News Movement surprised her with a trip from Expedia so her family may continue making happy memories.
➡️ bit.ly/4oUGbIX
➡️ bit.ly/4oUGbIX